Literature DB >> 30449528

Immunotherapy for Head and Neck Cancer.

Felix Sim1, Rom Leidner2, Richard Bryan Bell3.   

Abstract

The immune system has a vital role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). Immune evasion of cancer cells leads to progression of HNSCC. An understanding of this mechanism provides the basis for improved therapies and outcomes for patients. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. This article provides an overview of the interaction between immune infiltrating cells in the tumor microenvironment, and the immunologic principles related to HNSCC. Current immunotherapeutic strategies and emerging results from ongoing clinical trials are presented.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adoptive T-cell transfer; Checkpoint inhibitor; Head and neck cancer; Immunotherapy; Oncolytic virus; Squamous cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30449528     DOI: 10.1016/j.coms.2018.09.002

Source DB:  PubMed          Journal:  Oral Maxillofac Surg Clin North Am        ISSN: 1042-3699            Impact factor:   2.802


  15 in total

Review 1.  Mechanism of tumour microenvironment in the progression and development of oral cancer.

Authors:  Mohd Mughees; Anindita Sengupta; Sapna Khowal; Saima Wajid
Journal:  Mol Biol Rep       Date:  2021-01-25       Impact factor: 2.316

2.  TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC.

Authors:  Weili Kong; Yinze Han; Hailing Gu; Hui Yang; Yi Zang
Journal:  Biochem Biophys Rep       Date:  2022-10-13

3.  ANLN promotes carcinogenesis in oral cancer by regulating the PI3K/mTOR signaling pathway.

Authors:  Bing Wang; Xiao-Li Zhang; Chen-Xi Li; Ning-Ning Liu; Min Hu; Zhong-Cheng Gong
Journal:  Head Face Med       Date:  2021-06-03       Impact factor: 2.151

Review 4.  Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.

Authors:  Kevin O Saunders
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

Review 5.  PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.

Authors:  Silvia Pesce; Marco Greppi; Francesco Grossi; Genny Del Zotto; Lorenzo Moretta; Simona Sivori; Carlo Genova; Emanuela Marcenaro
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

6.  Oncologic Outcomes of Patients With Sarcomatoid Carcinoma of the Hypopharynx.

Authors:  Liyuan Dai; Qigen Fang; Peng Li; Fei Liu; Xu Zhang
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

Review 7.  Biomaterial-based strategies for maxillofacial tumour therapy and bone defect regeneration.

Authors:  Bowen Tan; Quan Tang; Yongjin Zhong; Yali Wei; Linfeng He; Yanting Wu; Jiabao Wu; Jinfeng Liao
Journal:  Int J Oral Sci       Date:  2021-03-16       Impact factor: 6.344

Review 8.  Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy.

Authors:  Miguel Angel Galván Morales; Raúl Barrera Rodríguez; Julio Raúl Santiago Cruz; Luis M Teran
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

9.  Prognostic Potential of Tumor-Infiltrating Immune Cells in Resectable Oral Squamous Cell Carcinoma.

Authors:  Ana Caruntu; Liliana Moraru; Mihai Lupu; Florina Vasilescu; Marius Dumitrescu; Mirela Cioplea; Cristiana Popp; Alexandra Dragusin; Constantin Caruntu; Sabina Zurac
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

Review 10.  Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.

Authors:  Zi Yin; Min Yu; Tingting Ma; Chuanzhao Zhang; Shanzhou Huang; Mohammad Reza Karimzadeh; Amir Abaas Momtazi-Borojeni; Sheng Chen
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.